Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Izotropic Corp C.IZO

Alternate Symbol(s):  IZOZF

Izotropic Corporation is a Canada-based medical device company. The Company is engaged in the development and commercialization of IzoView, a computed tomography (CT) imaging system, which produces cross-sectional images that can be imaged in the 30 centi-meter aperture by computer reconstruction of x-ray transmission data for non-invasive visualization of tissue. The IzoView is for use in the... see more

CSE:IZO - Post Discussion

View:
Post by Mykalj on Mar 15, 2021 8:54am

News

Izotropic Corporation
Symbol IZO
Close 2021-03-12 C$ 0.83
Recent Sedar Documents

ORIGINAL: Izotropic Appoints Dr. John McGraw as Chief Executive Officer

2021-03-15 08:00 ET - News Release

 

(via TheNewswire)



   

VANCOUVER, BC - TheNewswire - March 15, 2021 – Izotropic Corporation (“ Izotropic ”) (C NSX : IZO. CN ) (OTC: IZOZF ) (FSE: 1R3 ), a company developing 360-degree, high-resolution 3D dedicated breast CT imaging technology for the earlier detection and diagnosis of breast cancers, announces that its Board of Directors has appointed Dr. John McGraw as Chief Executive Officer, effective April 5, 2021. Dr. McGraw previously held the position of Executive Vice President of Commercial Operations with Izotropic. 

Also, effective April 5, 2021, Robert Thast has resigned from his position as President and Chief Executive Officer and will remain a Director and Special Advisor to Izotropic. 

 “Izotropic is one of those rare companies with an imaging technology that can dramatically improve a patient’s experience with breast cancer detection. I am honored to work with incredibly talented people who are all focused on improving breast cancer outcomes. In my work with the company over the past year, it has been clear that there is tremendous enthusiasm from patients, doctors, and clinics, which suggests strong market demand for our future products,” said Dr. McGraw. “We are executing and continue to move forward with confidence due to the strong foundations Mr. Thast has built. He has developed a truly impressive medical device company with strong business and scientific leadership, achieved the issuance of key patents, and has the company’s development efforts well underway. I look forward to continuing to work with him as we enter our next stages of development.” 
 

Dr. McGraw has 21 years of experience in the medical device field, including previous senior executive roles as Vice President of Operations for Novadaq Technologies Inc. (NASDAQ: NCVQ), a medical device imaging company that was acquired by Stryker Corporation for U.S. $701M in 2017. He was also Senior Vice President Business Development & Strategy for CML HealthCare Inc (TSX: CLC), one of Canada’s largest medical imaging service and laboratory medicine providers, which was acquired for CA$1.2B in 2013. 
 

“I can think of no one better to move Izotropic forward through to commercialization than John McGraw,” said Robert Thast, CEO. “Over the past year, he has steadily advanced development in all key operational areas, demonstrating expertise and multi-disciplinary management capabilities in areas of product development, clinical studies, regulatory and reimbursement processes, manufacturing, sales, and marketing. He has all of the tools and resources required, including an extensive database of contacts at all levels within the industry to draw upon going forward. With his overall experience running medical device companies and a track record with billion-dollar acquisitions, I am confident in his ability to continue to grow the company and commercialize IZOview Breast CT”.   

ON BEHALF OF THE BOARD 


For investor relations inquiries contact: 
James Berard 
Email:  jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1 

About Izotropic Corporation 

Izotropic Corporation is commercializing dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers. Extensive preliminary studies have found that breast CT may be able to routinely detect small breast tumors in the 3-5 mm size range. The median size of breast cancer found using mammography is approximately 11 mm. Routine detection of 3 mm lesions would result in 1.5 year earlier detection over mammography. 

The initial indication for use for breast CT as a diagnostic device has been confirmed. Forthcoming business objectives include identifying additional indications for use, development of accessories, and additional products, all aimed at making breast CT an indispensable tool for improving the outcomes of breast cancer. 

Additional information about Izotropic Corporation can be found on its website at  izocorp.comand by reviewing its profile on SEDAR at  sedar.com

Comment by gunzod on Mar 15, 2021 10:45am
This is very positive move  for IZO going forward,
Comment by Bakunin6 on Mar 15, 2021 11:48am
Still a nice buy under $1.15
Comment by Jarred on Mar 15, 2021 1:46pm
It is a tremendously positive move, Mcgraw will get it done!!  He has proven that in the past. 
Comment by Mykalj on Mar 16, 2021 8:28am
As they say volume speaks volumes. A little over 1.6 million shares on the news from yesterday. Onwards!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities